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Abstract
Background: Systemic sclerosis (SSc) is an autoimmune connective tissue disorder whose aetiology is not fully under-
stood. Skin fibrosis and visceral organs involvement are the hallmarks, and the heart could be disproportionately or subtly 
involved. Cardiovascular manifestations could include arrhythmias, pericarditis, myocardial fibrosis, pulmonary hyperten-
sion and congestive heart failure. Pulmonary involvement could cause lung fibrosis, arteriolar thickening, and pulmonary 
hypertension. The presence of  these manifestations confers a poor prognosis.
Case Report: The case report presents a 50-year-old male patient with generalized skin sclerosis, hypo and hyperpigmented 
skin lesions, dyspnoea at rest, displaced apical impulse, tachycardia and pan-systolic murmur at the apex radiating to the 
axilla. Echo cardiography features showed ejection fraction of  33.3% with dilated atrial and ventricular chambers. 
Conclusions: We present a case systemic sclerosis complicated by biventricular heart failure and pulmonary hypertension.
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Introduction
Systemic sclerosis (SSc) is a relatively rare connective tissue 
disorder of  unknown aetiology, with an incidence ranging from 
2 to 20 per million population per year and a female-to-male 
ratio of  roughly 3:1 [1, 2]. Systemic sclerosis is characterised 
by the skin and visceral organs fibrosis, in which the heart is 
frequently and severely involved. Studies have shown that up 
to 40 to 70% of  patients with SSc may be harbouring one form 
of  cardiac complication or the others [1, 3]. Sclerodermic heart 
disease, alone or in association with interstitial lung fibrosis and 
pulmonary hypertension, is one of  the main determinants of  
overall prognosis in SSc [4].
Primary cardiac involvement develops as a direct consequence of  
SSc involvement of  the heart in myocardial fibrosis may manifest 
as myocardial damage, fibrosis of  the conduction system, 
pericardial and, less frequently, as valvular disease [5]. Also, cardiac 
complications in SSc may develop as a secondary phenomenon 
due to pulmonary arterial hypertension and renal crises [5].
Diffused sclerodermatous alteration describes the classic 
picture of  SSc patient with visceral organ involvement or 
limited cutaneous form. Here we present the case of  a 50-year-
old Nigerian with advanced systemic sclerosis complicated by 
pulmonary hypertension and biventricular heart failure.
Case Report
50 years old roadside automobile mechanic who had a history of  
consistent contact with automobile oil and vibrating equipment 
presented to our clinic. His presenting symptoms include 
initial generalised body swelling and progressive hardening and 
dyspigmentation of  the scalp, face, chest, the back, and the upper 
and lower limbs in the preceding two years. A year following, 
the patient presented to the clinic with progressively worsening 
dyspnoea, poor effort tolerance, later orthopnoea, paroxysmal 
nocturnal dyspnoea and bilateral leg swelling up to the knee. 
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There were no symptoms suggestive of  renal failure. He was 
not on any cardiotoxic medication. The patient had no previous 
history of  systemic hypertension, diabetes melitus and no family 
history of  heart disease. 
Physical examination revealed bilateral pitting pedal oedema up 
to the knee, skin dyspigmentation (hypo and hyperpigmented 
lesions) on the scalp with scarring alopecia, face, and chest, back, 
extensor surfaces of  both forearms and legs (Figures 1, 2 and 
3). There were sclerodactyly and loss of  pulp substance of  the 
digits. Patchy scarring alopecia of  the frontal and vertex region 
was noticed. Patient’s mouth was deformed with peri-oral loss of  
soft tissue (Figure 4). Cardiac examination revealed tachycardia; 
blood pressure was 90/60mmHg; the maximum impulse was 
displaced laterally on sixth intercostal space anterior axillary 
line. Heart sound was normal with a pan systolic murmur. The 
anti-nuclear antibody testing was positive-homo and speckled 
pattern, and Scl-70 antibody was positive. Chest x-ray revealed 
cardiomegaly without evidence of  lung fibrosis. The hilar vessels 
were engorged with the upward diversion of  pulmonary vessels. 
There was blunting of  costophrenic recesses. Echocardiography 
revealed; LVDD:55.9mm, LVSD:46.9mm, RVD:36.6mm, 
LAD:45.5mm, IVST:9.7mm, PWTd: 9.0mm, AOD:31.7mm, 
and ACS:20.0mm. The left atrium and ventricles were dilated 
with reduced biventricular systolic function, global hypokinesia, 
left ventricular apical clots, and generalised spontaneous echo 
contrast. The right ventricular outflow tract was dilated, severe 
tricuspid, pulmonary and mitral regurgitation was noted. Left 
ventricular ejection fraction was 33.35%, pulmonary arterial 
systolic pressure 33+10mmHg, dilated hepatic veins with reduced 
respiratory excursion compatible with pulmonary hypertension 
with biventricular failure and left ventricular intracardiac apical 
clot (Figure 5). Electrocardiography showed low limb leads 
voltage, LAE, PR interval-0.20 seconds, displaced transition zone 
(left), and ST-segment elevation in anterolateral leads.
Hematology reports showed Haemoglobin of  10.3g/dl, ESR-
32mmol/hr (Westergren method). Electrolyte, urea, and creatinine 
were within normal limits. An assessment of  biventricular heart 
failure in a patient with SSc-associated PAH was made, with 
NYHA class III dyspnoea. Treatment for congestive cardiac 
failure was optimised with furosemide, lisinopril, spironolactone, 
digoxin, and warfarin, with the aim of  achieving an international 
normalised ratio of  between 2-3. The patient was also placed 
on tab hydroxychloroquine. He was given a referral to the 
Rheumatologist and Cardiologist. The patient was doing well on 
these medications until he became non-compliant. He eventually 
had a cardioembolic stroke and died about two years after 
discontinuation of  care with the specialists. 
Discussion
Cardiac involvement in SSc can be categorized as involving 
the: myocardium, conduction system, pericardium, blood 
vessels [6] and the indirect effect following the development of  
pulmonary hypertension and renal crisis [7]. Both cardiovascular 
and pulmonary complications are responsible for the bulk of  
morbidities and mortalities associated with SSc [5-7].
Figure 1. Diffuse thickening and depigmentation of  the skin.
Figure 2. Diffuse thickening and depigmentation of  the skin.
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The clinical presentation varies extensively in patients with 
SSc and cardiac involvement [5-7]. Our patient presents with 
a combination of  the symptoms of  right and left heart failure. 
These include pulmonary congestion, dyspnoea with exertion, 
paroxysms of  nocturnal dyspnoea, orthopnoea, and pedal 
oedema. The indolent nature of  dyspnoea and poor effort 
tolerance might be unconnected with the initial development of  
pulmonary hypertension and subsequent right heart failure and 
congestion. Orthopnea or paroxysms of  nocturnal dyspnoea are 
unusual symptoms in the absence of  left heart involvement. The 
other features of  severe pulmonary hypertension not manifested 
by this patient are chest pain, dizziness, palpitations,syncope and 
sudden cardiac death following the development of  arrhythmias 
or acute right ventricular failure [2, 8, 9].
Other findings that suggest the involvement of  other components 
of  the heart in this patient is the presence of  an asymptomatic 
minimal pericardial effusion. Pericarditis could present with 
pericardial effusion or uremic pericarditis if  there is associated 
scleroderma renal disease. Acute pericarditis in SSc has also been 
documented to present with diffuse ST-segment elevation [10].
Patients with arrhythmias may experience palpitations due either 
to bradycardia or tachycardia [4].
In the index case, doppler echocardiography shows evidence of  
biventricular systolic dysfunction. Previous studies have shown 
both diastolic and systolic dysfunction could occur in SSc [1, 
5-7, 11]. However, diastolic dysfunction is a common cardiac 
abnormality in patients with SSc compared to systolic dysfunction 
[5-7, 11]. Diastolic dysfunction is a non-invasive measure of  
myocardial fibrosis, and ventricular filling stiffness [6]. In a 
multicenter series of  patients with SSc in France, the prevalence 
of  systolic dysfunction was 1.4% while diastolic dysfunction was 
commoner at 17.7% as reported by Groote et al., [12]. Champion 
et al., reported systolic dysfunction incidence of  11-15% [7]. 
When present, systolic dysfunction has been related to the 
simultaneous presence of  coronary artery disease or hypertensive 
heart disease [13]. Although our patient had electrocardiography 
evidence of  anterolateral ischemia, he has no previous history of  
systemic hypertension, and coronary angiography was not done 
partly because of  limitation of  funds and its scarce availability 
Figure 3. Scarring Alopecia of  the scalp.
Figure 4. Peri-oral soft loss.
Figure 5. Apical three-chamber view Transthoracic Echocardiography showing the left atrium, left ventricle,  left ventricular 
outflow tract, dilated left atrium and ventricle with the apical clot.
Akinboro AO, Akintunde AA, Akinlade M, Audu MB. A Case Report of  Systemic Sclerosis Complicated by Biventricular Heart Failure, Pulmonary Hypertension and Review of  
Literature. Int J Cardiol Res. 2017;4(3):91-94..
94
   OPEN ACCESS                                                                                                                                                                              http://scidoc.org/IJCRR.php
in our environment. Our patient had digital ulcerations and 
reduction of  pulp substance, an independent risk factor for 
depressed left ventricular ejection factor. Other independent risk 
factors associated with reduced left ventricular ejection (LVEF) 
include age, male gender, myositis, and lack of  treatment with 
calcium blockers [14]. In difference to Allanore et al. study, 
the presence of  reduced LVEF was not associated with typical 
cardiovascular risk factors but an indicator SSc severity and 
markers of  microvasculopathy [13].
Another important observation in this report is the elevated 
pulmonary arterial pressure demonstrated with Doppler 
echocardiography without chest x-ray evidence of  lung fibrosis. 
However, high-resolution chest computerized tomography and 
pulmonary function test could be not performed to accurately 
assess for lung fibrosis. The reported prevalence of  PH in SSc 
varied widely. Condliffe et al., [15], 2009 reported a prevalence 
of  10% to 12%, and prevalence ranged from 4.9% and 26.7% 
depending on the diagnostic tools employed [8]. PH is considered 
regarded as a harbinger of  increased morbidity and mortality in 
SSc [2, 9, 16]. Pulmonary hypertension in SSc may be associated 
with pulmonary fibrosis or may develop due to vascular narrowing 
or occlusion in cases with or without minimal pulmonary fibrosis 
[9]. The pathophysiologic consequence of  this anomaly is the 
right heart failure [2, 9, 16]. The risk factors for PH in clinical 
practice include factors such as: decreased diffusion capacity 
of  lungs for carbon monoxide (DLCO), increased ratio of  
forced vital capacity to DLCO, the presence of  anti-centromere 
antibodies, anti-nuclear antibody (ANA) pattern, and increased 
disease duration [16]. The positive anti topoisomerase has also 
been associated with rapid progressive skin thickening, pulmonary 
fibrosis and renal crisis [17].
There was widespread regurgitant murmurs: tricuspid, mitral, 
pulmonary and aortic in the present patient and the valve 
regurgitations especially mitral and tricuspid could be secondarily 
related to the ventricular dysfunction in this patient. Previously 
published studies have suggested scleroderma rarely involve 
the valves [5-7, 18], but any valve could be involved [18-20].
Meune et al., [18] reported the presence of  small masses similar 
to Libman-Sacks vegetations, aortitis, aortic regurgitation (AR), 
and an increased frequency of  mitral valve prolapse. Other study 
confirmed mitral valve as the most commonly affected valve [19].
Faccini et al., [20] also reported the significant greater prevalence 
of  valvular abnormalities within five years in-patient with diffuse 
SSc. 
Conclusion
Cardiopulmonary involvement portends grave consequences 
for patients with systemic sclerosis. Pulmonary hypertension 
and cardiovascular dysfunctions either primary or secondary 
frequently complicates SSc and are probably under-recognised due 
to a shortage of  funds or non-availability of  advance investigation 
modalities in our environment. Early screening of  patients with 
SSc using echocardiography and lung function test will go long 
way to significantly contribute to early recognition and treatment 
of  affected patients.
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